I doubt very much such a ratio would be used, but an R/S isn't beyond the possibilities. I believe when the unblind we'll see a share price of $1 or more. At that time I don't know that investors wouldn't go along with something like a one for four which could put the company on the Nasdaq, as well as giving them far more flexibility in partnering. Actually even a one for two could be sufficient as the partnership should move the price at that time well over $4 if we had the 1 for 2 before it.
Long term, I don't believe it's necessary, but it could be desirable to move to the Nasdaq sooner, but really not that much sooner. With our current share structure, once approval of the vaccine is anticipated, even without a partnership, a market cap in the billions is very possible, so we should at least be close to a Nasdaq listing, and we could be on the AMEX if we choose.
I believe the key is unblinding and watching what happens, it's very possible the data is so compelling the $4 price is achieved immediately and sustained. When this trial is unblinded, I believe a lot of people will want it in their portfolio, likewise Institutions, no telling how high it may go if that is the case.
TSLA currently has a market cap of over 77 billion dollars, to the best of my knowledge they've yet to make a profit. I like the car, but I'm unsure if they'll ever be profitable. The perception is that they're successful, and that's what has the stock where it is. I believe once trial results are out NWBO may be perceived to be very successful even if it hasn't yet occurred. Perception is often more important than reality. My favorite comparison is IMGN and SGEN, I believe the difference between the companies is largely that SGEN is perceived as successful, while IMGN is not, if you look at their technologies you might conclude IMGN's are superior, certainly close, but that hasn't mattered. Look for yourself, see if it's just my opinion.
Gary
